Division of Adult Reconstruction, Department of Orthopedic Surgery, NYU Langone Orthopedic Hospital, NYU Langone Health, New York, NY.
J Arthroplasty. 2019 Nov;34(11):2669-2675. doi: 10.1016/j.arth.2019.06.038. Epub 2019 Jun 26.
Opioid prescriptions and subsequent opioid-related deaths have increased substantially in the past several decades. Orthopedic surgery ranks among the highest of all specialties with respect to the amount of opioids prescribed. We present here the outcomes of our opioid-sparing pain management pilot protocol for total hip arthroplasty (THA).
A retrospective study was conducted to assess outcomes before and after the implementation of an opioid-sparing pain management protocol for THA. Patients were divided into 2 cohorts for comparison: (1) traditional pain management protocol and (2) opioid-sparing pain management protocol. The Hip Disability and Osteoarthritis Outcome Score for Joint Replacement, pain severity using a Visual Analog Scale, and inpatient morphine milligram equivalents (MMEs) per day were compared between the 2 cohorts.
No statistically significant difference was observed in Hip Disability and Osteoarthritis Outcome Score for Joint Replacement between the 2 cohorts at any time point (P > .05). Although there was a significant decrease in pain scores over time (P < .01), there was no statistically significant difference in the rates of change between the 2 pain management protocols at any time point (P = .463). Inpatient opioid consumption was significantly lower for the opioid-sparing cohort in comparison to the traditional cohort (14.6 ± 16.7 vs 25.7 ± 18.8 MME/d, P < .001). Similarly, the opioid-sparing cohort received significantly less opioids than the traditional cohort during the post discharge period (13.9 ± 24.2 vs 80.1 ± 55.9 MME, P < .001).
The results of this study suggest that an opioid-sparing protocol reduces opioid consumption and provides equivalent pain management and patient-reported outcomes during the 90-day THA episode of care relative to a traditional opioid-based regimen. These findings may help decrease the risk of adverse events associated with postoperative opioid use and provide a means of decreasing the opioid footprint in clinical practice.
在过去几十年中,阿片类药物处方和随后的阿片类药物相关死亡人数大幅增加。在所有专业中,骨科手术的阿片类药物处方量都位居前列。我们在此介绍我们的全髋关节置换术(THA)阿片类药物节约型疼痛管理试验方案的结果。
进行了一项回顾性研究,以评估实施 THA 阿片类药物节约型疼痛管理方案前后的结果。患者分为 2 组进行比较:(1)传统疼痛管理方案和(2)阿片类药物节约型疼痛管理方案。使用髋关节残疾和骨关节炎结果评分(HHS)比较两组之间的髋关节置换,使用视觉模拟量表(VAS)比较疼痛严重程度,以及住院吗啡毫克当量(MME)/天。
在任何时间点,两组之间的 HHS 均无统计学差异(P >.05)。尽管疼痛评分随时间显著下降(P <.01),但在任何时间点,两组之间的变化率均无统计学差异(P =.463)。与传统组相比,阿片类药物节约组的住院阿片类药物消耗量明显较低(14.6 ± 16.7 与 25.7 ± 18.8 MME/d,P <.001)。同样,与传统组相比,阿片类药物节约组在出院后期间接受的阿片类药物也明显较少(13.9 ± 24.2 与 80.1 ± 55.9 MME,P <.001)。
本研究结果表明,与传统的基于阿片类药物的方案相比,阿片类药物节约方案可减少阿片类药物的消耗,并在 90 天的 THA 治疗期间提供等效的疼痛管理和患者报告的结果。这些发现可能有助于降低与术后阿片类药物使用相关的不良事件风险,并为减少临床实践中的阿片类药物使用提供一种方法。